维普中文期刊产品整合服务

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia

查看全文 作  者:George Zaki [1,2]Ghali;Michael George Zaki [3,4]Ghali 高影响力作者 机构地区:[1]United States Environmental Protection Agency,Arlington,VA,USA;[2]Department of Toxicology,Purdue University,West Lafayette,IN,USA;[3]Department of Neurological Surgery,University of California San Francisco,San Francisco,CA,USA;[4]Department of Neurobiology and Anatomy,Drexel University College of Medicine,Philadelphia,PA,USA高影响力机构 出  处:《Neural Regeneration Research》索引2020年第15卷第12期,共18页高影响力期刊 摘  要:Nafamostat mesylate,an apparent soi-disant panacea of sorts,is widely used to anticoagulate patients undergoing hemodialysis or cardiopulmonary bypass,mitigate the inflammatory response in patients diagnosed with acute pancreatitis,and reverse the coagulopathy of patients experiencing the commonly preterminal disseminated intravascular coagulation in the Far East.The serine protease inhibitor nafamostat mesylate exhibits significant neuroprotective effects in the setting of neurovascular ischemia.Nafamostat mesylate generates neuroprotective effects by attenuating the enzymatic activity of serine proteases,neuroinflammatory signaling cascades,and the endoplasmic reticulum stress responses,downregulating excitotoxic transient receptor membrane channel subfamily 7 cationic currents,modulating the activity of intracellular signal transduction pathways,and supporting neuronal survival brain-derived neurotrophic factor/TrkB/ERK1/2/CREB,nuclear factor kappa B.The effects collectively reduce neuronal necrosis and apoptosis and prevent ischemia mediated disruption of blood-brain barrier microarchitecture.Investigational clinical applications of these compounds may mitigate ischemic reperfusion injury in patients undergoing cardiac,hepatic,renal,or intestinal transplant,preventing allograft rejection,and treating solid organ malignancies.Neuroprotective effects mediated by nafamostat mesylate support the wise conduct of randomized prospective controlled trials in Western countries to evaluate the clinical utility of this compound. 关 键 词:apoptosis cerebrovascular EXCITOTOXICITY infarction ISCHEMIA nafamostat mesylate necrosis neuroprotection serine protesae subarachnoid hemorrhage
相关文献

参考文献(204)

引证文献(4)

耦合文献(3)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费